

# Lamivudine + zidovudine



Essential medicine status ✓

Section: [6. Anti-infective medicines](#) > [6.4. Antiviral medicines](#) > [6.4.2. Antiretrovirals](#) > [6.4.2.5. Fixed-dose combinations of antiretrovirals](#)

EMLc

ATC codes: **J05AR01**

Indication	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified <b>ICD11 code: 1C62.Z</b>
INN	Lamivudine + zidovudine
Medicine type	Chemical agent
List type	Core (EML) (EMLc)
Formulations	Oral > Solid: 30 mg + 60 mg Tablet (EMLc) ; 150 mg + 300 mg Tablet (EML)
EML status history	First added in 2007 ( <a href="#">TRS 946</a> ) Changed in 2007 ( <a href="#">TRS 950</a> ) Changed in 2009 ( <a href="#">TRS 958</a> ) Changed in 2015 ( <a href="#">TRS 994</a> )
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> .
Wikipedia	<a href="#">Lamivudine + zidovudine</a>
DrugBank	<a href="#">Lamivudine</a> , <a href="#">Zidovudine</a>

## Summary of evidence and Expert Committee recommendations

The Expert Committee recommended the removal of lamivudine + zidovudine 150 mg + 300 mg from the EMLc to be in alignment with the recommendations of the Inter-Agency Task Team on Prevention and treatment of HIV in Pregnant Women, Mothers and their Children (1). References: 1. Update to the optimal list of paediatric ARV formulations. IATT Meeting Report, Geneva, Switzerland, 11-12 September 2013 Geneva: World Health Organization; 2013. Available from: <http://apps.who.int/medicinedocs/documents/s21435en/s21435en.pdf>.

